Cited by 36Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchAmyotrophic Lateral Sclerosis Research

Pathology of early-onset Alzheimer's disease cases bearing the Thr113-114ins presenilin-1 mutation

Singleton, A. B.·2000·Brain

Abstract

Most cases of familial presenile Alzheimer's disease are caused by mutations in the presenilin-1 (PSEN-1) gene, most of these mutations being missense mutations. A mutation in the splice donor site of intron 4 of PSEN-1 has been described recently which results in aberrant splicing of PSEN-1 mRNA, causing insertion of an additional amino acid, Thr113-114ins, into the protein. We studied the neuropathology of four cases bearing this mutation in an attempt to clarify the pathology of this hereditary form of Alzheimer's disease and to determine whether it differs from other familial forms of the disease. The disease presented as a progressive cognitive decline, myoclonus and seizures developing later in the disease, a feature common to PSEN-1-linked Alzheimer's disease. The course of the disease was relatively rapid, death occurring approximately 6 years after onset. Pathology in the intron 4 cases demonstrated a severe Alzheimer's disease pathology with abundant deposition of ss-amyloid (Ass) 1-42 senile plaques and the formation of neurofibrillary tangles. Amyloid angiopathy was present in these cases and was readily demonstrated by Ass 1-40 staining, particularly in the cerebellum. Cases with the intron 4 mutation appear clinically and pathologically similar to other cases of early-onset Alzheimer's disease bearing PSEN-1 mutations.

Integrity signals

Registry

Crossref · 10.1093/brain/123.12.2467

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Human PSEN1 mutation carriers have notable BBB breakdown and cerebrovascular dysfunction including cerebellar amyloid angiopathy and CAA, disrupted meningeal, subpial, and cortical arterioles, degeneration of pericytes and SMCs, cerebral perivascular amyloid deposits, and diminished FDG transport across the BBB in an early asymptomatic stage.

    “Human PSEN1 mutation carriers have notable BBB breakdown and cerebrovascular dysfunction including cerebellar amyloid angiopathy and CAA (143, 183, 274, 280, 354, 389, 440, 500, 544, 573, 639, 668); disrupted meningeal, subpial, and cortical arterioles (274, 389, 440); degeneration of pericytes and SMCs (573); cerebral perivascular amyloid deposits (25, 274, 289, 354, 573, 668); and diminished FDG”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [544]

  • Cerebrovascular pathology with BBB breakdown was shown by neuropathological studies in patients with specific PSEN1 mutations including T113-114 insertion, P117L, M139V, M146V, L153V, H163R, E184D, G209V, A260V, C260T, E280A, L282V, C285T, L420R, and Δe9 deletion.

    “Particularly, cerebrovascular pathology with BBB breakdown was shown by neuropathological studies in patients with PSEN1 T113-114 insertion (544), P117L (573, 639), M139V (183, 389), M146V (389), L153V (289), H163R (280), E184D (668), G209V (389), A260V (389), C260T (274), E280A (354), L282V (143), C285T (274), and L420R (440) missense mutations, and 𝚫 e9 deletion (280).”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [544]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Singleton, A. B.
Affiliations
Newcastle upon Tyne Hospital (GB)
Corresponding author
Singleton, A. B.
Venue
Brain
Published
2000-12-01
Volume
123
Issue
12
Pages
2467-2474
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2161584848
Cited by
36
References
3
Citations by year
2026: 2 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 1 · 2018: 4 · 2017: 1 · 2015: 2 · 2012: 1
FWCI
1.43
Type
journal article
Language
en
Open access
closed
Locations
  • Brain (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
early-onset Alzheimer's disease, presenilin 1, familial Alzheimer's disease, neuropathology, neurofibrillary tangles, amyloid angiopathy, myoclonus, seizures, cerebellum
MeSH terms
Adult, Alzheimer Disease, Cognition Disorders, Diagnosis, Differential, DNA Mutational Analysis, Electroencephalography, England, Female, Humans, Introns, Creutzfeldt-Jakob Syndrome, Membrane Proteins, Mutation, Myoclonus, Pedigree, Seizures, Fatal Outcome, Disease Progression, Presenilin-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review